European Primary Care Cardiovascular Society
Experts in dialogue - LDL-c goal attainment in high risk patients

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Comparison of low dose vs. high dose DOAC in patients with AF

3' education - Apr. 21, 2021 - Prof. Jan Steffel, MD

CV and renal benefit predicted by reduction in albuminuria in T2DM

10' education - Apr. 15, 2021 - Frederik Persson, MD

Weight loss induction by GLP-1RA in adults with overweight or obesity

10' education - Mar. 25, 2021 - Prof. Robert Kushner, MD

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD

The future of CV medicine: anti-inflammation

10' education - Mar. 5, 2021 - Prof. Paul Ridker, MD

Treat also older adults to lower LDL-c

5' education - Jan. 19, 2021 - Prof. Børge Nordestgaard, MD

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD

Widespread atherosclerosis in Swedish population

3' education - Dec. 3, 2020 - Prof. Göran Bergström, MD, PhD

Potentially no contradiction between omega-3 fatty acids trials

3' education - Dec. 3, 2020 - Prof. Deepak Bhatt, MD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Omega-3 carboxylic acid has no effect on MACE in high risk patients

3' education - Dec. 3, 2020 - Prof. Michael Lincoff, MD

A polypill with or without aspirin to reduce global CVD burden

3' education - Dec. 3, 2020 - Prof. Salim Yusuf, MD

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

An update on COVID-19 at the AHA Scientific Sessions

10' education - Dec. 3, 2020 - Anthony Fauci, MD

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD

CVD prevention with GLP-1 receptor agonists

10' education - Nov. 10, 2020 - Prof. Kamlesh Khunti, MD

To achieve lower LDL-c goals, combination therapy is necessary

3' education - Oct. 28, 2020 - Prof. Kausik Ray, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

Increased risk of new-onset HF into adulthood with preterm birth

Literature - May 11, 2021 - Crump C, et al. - JAMA Pediatr. 2021

Low gestational age at birth (<37 weeks) was associated with an increased risk for the development of HF into adulthood. The lower the gestational age of an infant at birth, the higher the risk for new-onset HF.

CV outcome trial with nonsteroidal MRA meets primary end point in patients with DKD

News - May 11, 2021

In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.

1 in 4 patients with myocardial infarction experiences atypical symptoms

Literature - May 10, 2021 - Lykkemark Møller A et al. - Eur Heart J Acute Cardiovasc Care. 2021

MI patients with atypical symptoms had a lower chance of receiving an emergency dispatch, and higher 30-day mortality compared to MI patients with chest pain. Breathing problems was the most common atypical symptom.

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD
Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and Kastelein talk about this topic in depth and exchange views.

Experts in dialogue Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and prof. Kastelein talk about this topic and exchange their views on LDL-c lowering.

COVID-19 vaccine-induced atypical thrombosis and thrombocytopenia in some individuals

Literature - Apr. 26, 2021 - Scully M, et al. - N Engl J Med. 2021 Apr 16.

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

Scientifc Statement from the AHA on adverse pregnancy outcomes and CVD

Literature - Apr. 21, 2021 - Parikh NI et al. - Circulation. 2021

Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.

Comparison of low dose vs. high dose DOAC in patients with AF

3' education - Apr. 21, 2021 - Prof. Jan Steffel, MD
Prof. Steffel presents a subanalysis of the ENGAGE AF-TIMI 48 trial that compared lower dose edoxaban vs. approved higher dose edoxaban regimens for (net) clinical outcomes in patients with AF.

Prof. Steffel presents a subanalysis of the ENGAGE AF-TIMI 48 trial that compared lower dose edoxaban vs. approved higher dose edoxaban regimens for (net) clinical outcomes in patients with AF.

In patients with coronary disease CV benefit of colchicine is consistent

Literature - Apr. 19, 2021 - Fiolet ATL et al. - Eur Heart J 2021

A meta-analysis of 5 trials showed that colchicine reduced MACE by 25% compared to placebo or no colchicine with a low between-trial heterogeneity in a wide range of patients with coronary disease.

CV and renal benefit predicted by reduction in albuminuria in T2DM

10' education - Apr. 15, 2021 - Frederik Persson, MD
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

In real-world setting, hospital readmissions are frequent first 3 months post-discharge in HF

Literature - Apr. 15, 2021 - Wideqvist M, et al. - ESC Heart Fail. 2021

This 1 year follow-up study of patients with HF in a real-world setting showed that hospital readmissions frequently occurred during the first 3 months after discharge and were mainly caused by worsening HF and a higher number of co-morbidities.

Reduction of net clinical outcome with lower dose DOAC in AF

Literature - Apr. 15, 2021 - Steffel J et al. - J Am Coll Cardiol. 2021

Lower dose edoxaban regimen decreased the net clinical outcome of major bleeding, stroke/systemic embolism, and death compared to higher dose edoxaban regimen in patients with AF.

Agenda